Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
46.8M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
4.04M
-
Shares change
-
-1.89M
-
Total reported value, excl. options
-
$4.29M
-
Value change
-
-$2.29M
-
Put/Call ratio
-
2.47
-
Number of buys
-
20
-
Number of sells
-
-40
-
Price
-
$1.06
Significant Holders of Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) as of Q3 2025
76 filings reported holding OTLK - Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share as of Q3 2025.
Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.04M shares
of 46.8M outstanding shares and own 8.65% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.34M shares), Schonfeld Strategic Advisors LLC (715K shares), BlackRock, Inc. (370K shares), GEODE CAPITAL MANAGEMENT, LLC (306K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (211K shares), MILLENNIUM MANAGEMENT LLC (195K shares), COMMONWEALTH EQUITY SERVICES, LLC (113K shares), BANK OF AMERICA CORP /DE/ (90.5K shares), SIMPLEX TRADING, LLC (89.2K shares), and STATE STREET CORP (75.3K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.